Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
about
The role of transporters in toxicity and diseaseITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansMembrane transporters in drug developmentReduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK ModelIn Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIsIntegration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards.A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineIntracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levelsThe evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Hepatic drug transporters: the journey so far.Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.
P2860
Q26999452-E735ACA0-3602-4AA9-82C3-C6728AE790ADQ27022933-BDABC85F-26F7-4E49-B72E-1EB4CB28A89CQ29616802-5B299AA1-49A4-4A7E-B2B5-92693DF0959DQ30776360-2EA12514-35B0-4D7D-9620-041E3A3CCD78Q33571451-EA6ABBC2-59F3-4023-9B6B-B1163CCED1B4Q35127513-7A181901-2B2A-4B7E-AF06-C1D5C7835180Q36234390-890C4FD7-D734-4E30-AEBF-E1191261E8D3Q36693701-49D85816-2A1C-43AA-B78E-322581A07F63Q37228208-23E140E2-6516-468C-B8E3-266862E055ECQ37470663-6DC27CB0-3547-4292-95DF-1DC55807E1EFQ37504548-AF48BF11-6EFF-469C-8A53-D9D36CA73072Q37626169-E06AC9AE-F013-484D-AC15-B3F2750FBAA9Q37955160-71E32463-3978-40BE-B57A-28F1E638953DQ37998136-19E022D2-D2D8-4F85-91A3-A64AA9CAD40CQ38077993-634543DA-42F3-485B-9F17-542723668B23Q38084901-DF580C33-BCAB-411B-9C7E-C68204C0914BQ38233298-A17C3889-22A0-42D0-BE36-0FBCF073E5B3Q38560889-33F6A986-4BD5-4CC9-B1EE-04ABDDAEEA67Q39941536-72DD2C85-5FCE-4A31-9E5B-D85C48F81500Q41262080-F12D7F33-719B-4A03-9368-0FC2A26E5E15
P2860
Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@en
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@nl
type
label
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@en
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@nl
prefLabel
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@en
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@nl
P2093
P356
P1476
Mechanistic modeling of hepati ...... napsagatran and fexofenadine.
@en
P2093
Agnès Poirier
Christoph Funk
Thierry Lavé
P304
P356
10.1021/MP8002495
P407
P577
2009-11-01T00:00:00Z